
About Yungjin Pharmaceuticals
Yungjin Pharmaceuticals is a publicly listed company based in Seoul (South Korea) founded in 1952. Pharmaceutical products are manufactured in South Korea. The company has 628 employees. Its chief executive, as recorded, is Lee Chae Joon. Its website yungjin.co.kr draws about 29 thousand monthly visits. Yungjin Pharmaceuticals offers products and services including Pharmaceuticals and Health Foods. Its focus areas include Traditional Pharmaceuticals. Its legal entity is Yungjin Pharmaceutical Co., Ltd.
Company details
Yungjin Pharmaceuticals was established in 1952 and is headquartered in Seoul, South Korea. Operations are focused on the manufacturing of pharmaceutical products within the healthcare sector. The company is led by CEO Lee Chae Joon. Activities encompass production processes tailored to pharmaceutical standards, with a primary emphasis on domestic markets. Geographic presence remains centered in South Korea, supporting regional healthcare needs through established facilities.
- Headquarters Seoul, South Korea
- Employees 628
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website yungjin.co.kr/index.asp
- Social LinkedIn
- Legal Name Yungjin Pharm. Co. Ltd
- Annual Revenue$176.06 M (USD)0.88as on Dec 31, 2025
- Net Profit-$157.64 K (USD)-118.47as on Dec 31, 2025
- EBITDA$8.45 M (USD)-30.03as on Dec 31, 2025
- Employee Count628
Products & Services of Yungjin Pharmaceuticals
Yungjin Pharmaceuticals offers a comprehensive portfolio of products and services, including Pharmaceuticals and Health Foods.
Various prescription and over-the-counter medicines are developed and distributed for treating chronic and other health conditions.
Health foods and supplements are provided to support consumer well-being and nutritional needs.
People of Yungjin Pharmaceuticals
1 people are tracked at Yungjin Pharmaceuticals (1 in leadership); the tracked headcount is 628.
| Name | Role | Group |
|---|---|---|
Lee Chae Joon | CEO | Leadership |
Complete people profiles for Yungjin Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Yungjin Pharmaceuticals
Yungjin Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 003520 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jun 1973
- Listed onKRX: 3520
- Listed entityYUNGJIN PHARM. CO. LTD
- Exchange sectorHealth technology
- ISINKR7003520004
- Share price996.00 KRW (-1.29% on the day) · 2026-10-14
- Market capitalisation184,538,488,159.00 KRW
- EPS (diluted, trailing year)-34.21 KRW
- Volume (last session)264,171
Financials of Yungjin Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 254.26B KRW | -227.7M KRW | 12.20B KRW |
| 2024 | 252.04B KRW | 1.23B KRW | 17.44B KRW |
| 2023 | 234.90B KRW | -3.88B KRW | 11.81B KRW |
| 2022 | 218.38B KRW | -21.96B KRW | 316.8M KRW |
| 2021 | 196.07B KRW | -11.58B KRW | -6.50B KRW |
Detailed financial statements for Yungjin Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Yungjin Pharmaceuticals
The website of Yungjin Pharmaceuticals (yungjin.co.kr) receives about 28.9K visits a month and ranks #1,158,865 among all websites worldwide, #1,450 in Biotechnology and Pharmaceuticals.
- Monthly visits28.9K
▲ 2.4% vs previous month
- Unique visitors5.1K
per month
- Global rank#1,158,865
among all websites
- Category rank#1,450
Health · Biotechnology and Pharmaceuticals
- Bounce rate30%
- Pages per visit2.6
- Average visit4 min 17 sec
- DevicesDesktop 16% · Mobile 84%
Websites whose visitors overlap most with Yungjin Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
medical-tribune.co.kr | medical-tribune.co.kr | 100% | #1,257,589 | – | |
| choa.co.kr | 100% | 14K | #1,738,079 | View details | |
| medisobizanews.com | 99% | #283,693 | View details | ||
medipana.com | medipana.com | 99% | #266,587 | – | |
| hyundaipharm.co.kr | 99% | 25.8K | #1,103,659 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Yungjin Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Yungjin Pharmaceuticals
Complete news archive for Yungjin Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Yungjin Pharmaceuticals
Yungjin Pharmaceuticals was founded in 1952.
Yungjin Pharmaceuticals is headquartered in Seoul, South Korea.
Lee Chae Joon is the CEO of Yungjin Pharmaceuticals, as recorded in our data.
Yungjin Pharmaceuticals has 628 employees.
Annual revenue of Yungjin Pharmaceuticals is $176.06M as on Dec 31, 2025.
Yungjin Pharmaceuticals was established in 1952 and is headquartered in Seoul, South Korea. Operations are focused on the manufacturing of pharmaceutical products within the healthcare sector. The company is led by CEO Lee Chae Joon. Activities encompass production processes tailored to pharmaceutical standards, with a primary emphasis on domestic markets. Geographic presence remains centered in South Korea, supporting regional healthcare needs through established facilities.
Yungjin Pharmaceuticals offers Pharmaceuticals and Health Foods.
Yes, Yungjin Pharmaceuticals is publicly traded on KRX under the ticker symbol 003520.
Yungjin Pharmaceuticals operates through Yungjin Pharmaceutical Co., Ltd.
